On 12 January 2006 Protherics announced that the licensing agreement between Protherics and AstraZeneca for the global development and commercialisation of Protherics’ anti-sepsis product CytoFabTM had become effective, following the expiry of the Hart-Scott-Rodino waiting period in the US. This has triggered, inter alia, a GBP7.5 million equity investment by AstraZeneca in Protherics, in return for which Protherics will issue to AstraZeneca 10,990,621 Ordinary Shares (the “New Ordinary Shares”).
